Welcome to Mesothelioma.net - Turning Hope and Faith into Action.

Mesothelioma Study Reveals Extended Survival Combining TTF with Chemotherapy

The results were part of the Stellar phase 2 registration trial, which compares previously recorded results from treating mesothelioma with chemotherapy alone to treating the rare form of cancer using both chemotherapy and the Tumor Treating Fields. The researchers involved in the study gave patients diagnosed with malignant pleural mesothelioma pemetrexed and either cisplatin or carboplatin along with the TTF treatment, and found that their median overall survival got a boost of more than 6 months. They also found that the median progression free survival time for patients receiving the additional TTF treatment expanded by almost two full months as compared to chemotherapy alone, with clinical benefits seen in 97.2 percent of patients. Even more encouraging was the fact that the devices created no serious adverse effects beyond skin irritation, which was reported in 46% of patients.

Speaking of their findings,  Stellar trial investigator Dr. Giovanni Ceresoli of Bergamo, Italy’s Humanitas Gavazzeni Hospital said, “The final results of the Stellar trial demonstrate an impressive extension of median overall survival in the treatment of malignant pleural mesothelioma with no increase in systemic toxicity. Mesothelioma patients face an urgent unmet need for additional therapies that improve survival. Based on these data, I believe Tumor Treating Fields represent an extremely promising therapeutic option that, if approved, should be added to standard of care chemotherapy for the treatment of malignant pleural mesothelioma.” The chief science officer of Novocure, Dr. Eilon Kirson, echoed this comment, saying, “We are extremely pleased by the results of the Stellar trial. We believe the results support the use of Tumor Treating Fields in our first indication outside of the brain. We are now one step closer to commercializing Tumor Treating Fields as a treatment for malignant pleural mesothelioma.”

If you or someone you love has been diagnosed with mesothelioma and need information on clinical trials  or other resources, contact the Patient Advocates at Mesothelioma.net today at  1-800-692-8608.

Terri Oppenheimer

Terri Oppenheimer is an independent writer, editor and proofreader. She graduated from the College of William and Mary with a degree in English. Her dreams of a writing career were diverted by a need to pay her bills. She spent a few years providing copy for a major retailer, then landed a lucrative career in advertising sales. With college bills for all three of her kids paid, she left corporate America for a return to her original goal of writing. She specializes in providing content for websites and finds tremendous enjoyment in the things she learns while doing her research. Her specific areas of interest include health and fitness, medical research, and the law.

Get Your FREE Resources Sent Overnight

resources-shot_optimized
  • New treatment options
  • Veterans benefits & claims
  • $30 Billion asbestos trust fund information

– Or Call –
1-800-692-8608


Site Navigation

Where can I

Get Additional Help?

For over 15 years, we’ve provided the best FREE resources to mesothelioma patients and loved ones. Our resources include information on the leading treatment options and best doctors in your area; lessons learned from survivors; claims and benefits specifically for Veterans; and how to access your share of billions of dollars in trust fund money.

Get Your FREE Resources Sent Overnight

resources-shot_optimized
  • New Treatment Options
  • Veteran's Benefits & Claims
  • $30 Billion Asbestos Trust Fund Information

– Or Call –
1-800-692-8608

We are here to help you

support_staff

If you've been diagnosed with asbestos-related cancer, contact us at 1-800-692-8608 to find out if you are eligible to receive compensation. You can also fill out the form above to receive FREE information.

Quick Compensation - $30 Billion Trusts
$30 Billion Asbestos Trusts
Get Started